The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

The trial's primary analysis indicated an 83.7% efficacy ... decision made after consulting with a healthcare provider. The ...

mRESVIA is a RSV vaccine available in a pre-filled syringe ... Health Canada's approval is based on data from the Phase 3 ...

Big Data, Real World, Multi-State Study Finds RSV Vaccine Highly Effective in Protecting Older Adults Against Severe Disease, Hospitalization and Death Oct. 17, 2024 — This multi-state study is ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

RESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes ...

FDA Approvals and Expansions In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and ...

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Moderna surprised Wall Street with a third-quarter profit on Thursday, driven by robust COVID-19 vaccine sales and ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...